-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Buy on Biogen, Raises Price Target to $260

Benzinga·10/29/2026 16:09:04
TD Cowen analyst Phil Nadeau maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $250 to $260.